BR112014006180A2 - Substituted 4,5,6,6-tetrahydro-1h-pyrazol [4,3-c] pyridines, their use as medicaments and pharmaceutical preparations comprising the same - Google Patents

Substituted 4,5,6,6-tetrahydro-1h-pyrazol [4,3-c] pyridines, their use as medicaments and pharmaceutical preparations comprising the same

Info

Publication number
BR112014006180A2
BR112014006180A2 BR112014006180A BR112014006180A BR112014006180A2 BR 112014006180 A2 BR112014006180 A2 BR 112014006180A2 BR 112014006180 A BR112014006180 A BR 112014006180A BR 112014006180 A BR112014006180 A BR 112014006180A BR 112014006180 A2 BR112014006180 A2 BR 112014006180A2
Authority
BR
Brazil
Prior art keywords
pyrazol
tetrahydro
pyridines
pharmaceutical preparations
medicaments
Prior art date
Application number
BR112014006180A
Other languages
Portuguese (pt)
Inventor
Hessler Gerhard
Brendel Joachim
Pernerstorfer Josef
Lorenz Katrin
Steinmeyer Klaus
Wirth Klaus
Bialy Laurent
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014006180A2 publication Critical patent/BR112014006180A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

resumo patente de invenção: "4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas substituídas, seu uso como medicamento e preparações farmacêuticas que compreendem as mesmas". a presente invenção refere-se a 4, 5, 6, 7-tetraidro-1h-pirazol [4, 3-c] piridinas de fórmula i, ao seu uso como medicamento e a preparações farmacêuticas que compreendem as mesmas. os compostos de fórmula i agem sobre o canal de potássio de task-1. os compostos são adequados para o tratamento ou a prevenção de arritmias do átrio, por exemplo, fibrilação do átrio (af) ou flutter atrial.Summary Patent: "4,5,6,6-Tetrahydro-1h-pyrazol [4,3-c] substituted pyridines, their use as medicaments and pharmaceutical preparations comprising them". The present invention relates to 4,5,6,7-tetrahydro-1H-pyrazol [4,3-c] pyridines of formula I, their use as a medicament and pharmaceutical preparations comprising them. The compounds of formula I act on the task-1 potassium channel. The compounds are suitable for treating or preventing atrial arrhythmias, for example atrial fibrillation (af) or atrial flutter.

BR112014006180A 2011-09-16 2012-09-13 Substituted 4,5,6,6-tetrahydro-1h-pyrazol [4,3-c] pyridines, their use as medicaments and pharmaceutical preparations comprising the same BR112014006180A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306161 2011-09-16
PCT/EP2012/067995 WO2013037914A1 (en) 2011-09-16 2012-09-13 Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them

Publications (1)

Publication Number Publication Date
BR112014006180A2 true BR112014006180A2 (en) 2017-04-11

Family

ID=46832425

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006180A BR112014006180A2 (en) 2011-09-16 2012-09-13 Substituted 4,5,6,6-tetrahydro-1h-pyrazol [4,3-c] pyridines, their use as medicaments and pharmaceutical preparations comprising the same

Country Status (4)

Country Link
BR (1) BR112014006180A2 (en)
EA (1) EA025240B1 (en)
MX (1) MX2014003181A (en)
WO (1) WO2013037914A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134406A1 (en) * 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
WO2016073420A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted azetidinyl compounds as glyt1 inhibitors
RU2742305C2 (en) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Derivatives and methods of treating hepatitis b infections
WO2017097792A1 (en) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
CA3007699A1 (en) 2015-12-10 2017-06-15 Bayer Pharma Aktiengesellschaft Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
JOP20190284A1 (en) * 2017-06-14 2019-12-11 Bayer Pharma AG Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
WO2021207308A1 (en) * 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (en) 1982-02-17 1983-08-18 Lepetit Spa PROCEDURE FOR PREPARING PYRAZOLE (4,3-C) PYRIDINES
DE10332685A1 (en) 2003-07-18 2005-02-17 Bayer Healthcare Ag Use of a modulator of specific potassium channels, expressed preferentially in the atrium, for treatment and prevention of arrhythmia, coronary disease and hypertension
DE102005028845A1 (en) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
DE102005028862A1 (en) 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituted heterocycles, their use as medicament and pharmaceutical compositions containing them
NZ572231A (en) 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
US20130178475A1 (en) * 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS

Also Published As

Publication number Publication date
EA201490640A1 (en) 2014-09-30
EA025240B1 (en) 2016-12-30
MX2014003181A (en) 2015-08-05
WO2013037914A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
BR112014006180A2 (en) Substituted 4,5,6,6-tetrahydro-1h-pyrazol [4,3-c] pyridines, their use as medicaments and pharmaceutical preparations comprising the same
BR112014018990A8 (en) BENZOTHIAZOLE-6-ILACETIC ACID DERIVATIVES AND THEIR USE FOR TREATMENT OF AN INFECTION
BR112015021027A8 (en) therapeutic compounds, their uses, and pharmaceutical compositions
BR112015016001A2 (en) compounds, pharmaceutical compositions and their uses and method for treating or preventing bacterial infection
BR112013027121B8 (en) BICYCLIC HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS INCLUDING THEM, PROCESS FOR THE PREPARATION OF SAID COMPOUNDS AND THERAPEUTIC USES THEREOF
BR112014031234A2 (en) pyridinone and pyridazinone derivatives
BR112014007193A2 (en) pyrazoloquinolinone derivatives, their preparation and their therapeutic use
BR112015014458A8 (en) mannose derivatives, their intermediates, composition, use and preparation processes
BR112014022000A8 (en) pyrazol[1,5-a]pyrimidine-based compounds, their use and compositions comprising them
BR112015012366A2 (en) cxcr7 antagonists
BR112015011158A8 (en) triazolopyrazine, its use and pharmaceutical preparation
BR112014000938A2 (en) substituted quinazolines, their preparation and their use in pharmaceutical compositions
BR112014014452A2 (en) pyrazolpyridine derivatives, their preparation process and their therapeutic use
BR112015007083A2 (en) histone demethylase inhibitors
BR112016006651B8 (en) substituted quinolizine derivative compounds, pharmaceutical composition comprising them and use of said compounds
BR112014022214A2 (en) antibacterial phenolics
BR112015021549A2 (en) pyridine kinase cdk9 inhibitors
BR112015007366A2 (en) acylaminopyrimidine derivatives for the treatment of viral infections and other diseases
BR112014007163A2 (en) n-methyl-2 [3 ((e) -2-pyridin-2-yl-vinyl) -1h-indazol-6-ylsulfanyl] -benzamide pharmaceutical compositions
BR112014018767A8 (en) FUSED PYRROLDICARBOXAMIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM
BR112015021524A2 (en) sulfonyl quinoline derivatives and uses thereof
BR112015030315A2 (en) 4-alkynylimidazole derivative and medicament comprising the same as active ingredient
BR112014018795A2 (en) 1h-pyrrolo [2,3-b] pyridine derivatives and their use as kinase inhibitors
BR112014007223A2 (en) estra-1,3,5 (10), 16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
BR112015023356A2 (en) pyrrol [2,3-b] pyridine cdk9 kinase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2531 DE 09-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.